Moderna expects CDC to view its RSV vaccine as equal to rival shots
Moderna said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC) advisers to recommend the company's ...
STAT3d
Moderna ends collaboration with CRISPR company Metagenomi, parts ways with gene editing chief
Moderna invested part of its vaccine windfall into a new gene-editing startup, Metagenomi. Now it's backing out.
Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates
The PFS ready-to-use formulation will save pharmacists and clinicians time, potentially alleviating wait times and reducing ...
FierceBiotech2d
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
Much of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a decision expected in a matter ...
How Moderna's cost-cutting moves hit a Bay Area biotech
As Moderna eyes expanding beyond its Covid-19 vaccine, it is prioritizing certain R&D efforts, taking cost-cutting steps and ...
Why Moderna Stock Blasted 13% Higher Today
The company notched beats on both the top and bottom lines despite a major drop-off in demand for its famous product.
FierceBiotech3d
Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight
Earlier this year, Metagenomi had the spotlight with a $93.7 million IPO. Now, Moderna is exiting stage left on a partnership ...
Moderna’s Hold Rating Maintained Amidst Positive Sales Outlook and Awaited RSV Vaccine Launch
Needham analyst Joseph Stringer has maintained their neutral stance on MRNA stock, giving a Hold rating yesterday. Joseph Stringer has given ...
Moderna's Loss in Q1 Was Less Than Expected
The highlight of the quarter was undoubtedly the advancement of Moderna's pipeline, with three new vaccine programs moving toward Phase 3 clinical trials. This, coupled with the initiation of new ...
Moderna’s stock surges after better-than-expected quarterly results
Moderna’s stock jumped on Thursday as the company reported a narrower-than-expected first-quarter loss and looks to launch ...